| Kempers, Steven |
VAPAUS, NCT05180708: A Multicenter, Phase 3 Randomized, Double-Blind, Vehicle-Controlled Study Evaluating the Safety and Efficacy of QTORIN 3.9% Rapamycin Anhydrous Gel in the Treatment of Pachyonychia Congenita |
|
|
| Recruiting | 3 | 80 | Europe, US | QTORIN 3.9% rapamycin anhydrous gel, Vehicle | Palvella Therapeutics, Inc. | Pachyonychia Congenita | 06/23 | 06/23 | | |
NCT05643872: A Study Evaluating the Safety and Pharmacokinetics of QTORIN Rapamycin 3.9% Anhydrous Gel in the Treatment of Adults With Pachyonychia Congenita |
|
|
| Recruiting | 3 | 45 | US | PTX-022 | Palvella Therapeutics, Inc. | Pachyonychia Congenita | 10/23 | 11/23 | | |
TAK-279-3002, NCT06108544: A Study About How Well TAK-279 Works and Its Safety in Participants With Moderate-to-severe Plaque Psoriasis During 60 Weeks of Treatment With a Withdrawal and Retreatment Period |
|
|
| Recruiting | 3 | 1000 | Europe, Canada, US | TAK-279, Placebo, Apremilast | Takeda | Plaque Psoriasis | 07/25 | 06/26 | | |
NCT05005845: NFX-179 Topical Gel Treatment for Adults With Neurofibromatosis 1 (NF1) and Cutaneous Neurofibromas (cNF) |
|
|
| Completed | 2 | 199 | US | NFX-179 gel, NFX-179 topical gel, Vehicle gel, NFX-179 vehicle gel | NFlection Therapeutics, Inc. | Cutaneous Neurofibroma, Neurofibromatosis 1 | 10/23 | 10/23 | | |
NCT06108024: A Trial to Evaluate the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratosis |
|
|
| Recruiting | 2 | 60 | US | SM-020 gel 1.0%, Vehicle gel | DermBiont, Inc. | Seborrheic Keratosis | 09/24 | 10/24 | | |
| Recruiting | 2 | 99 | Europe, Canada, US, RoW | Placebo/Daxdilimab, Daxdilimab, HZN-7734 | Amgen, Horizon Therapeutics Ireland DAC | Discoid Lupus Erythematosus | 07/24 | 12/24 | | |
NCT06074315: Evaluation of the Effectiveness of Nail Genesis DLSO Product for Onychomycosis |
|
|
| Recruiting | N/A | 338 | US | Nail Genesis DLSO Product, Nail Genesis DLSO Product (vehicle only) | Nail Genesis LLC | Distal Lateral Subungual Onychomycosis, Onychomycosis | 01/25 | 01/25 | | |
